One of the key public health strategies in coronavirus 2019 disease (COVID-19) management is the early detection of infected individuals to limit the transmission. As a result, serological assays have been developed to complement PCR-based assays. Here, we report the development of a flow cytometry-based assay to detect antibodies against full-length SARS-CoV-2 Spike protein (S protein) in COVID-19 patients. The assay is time-efficient and sensitive, being able to capture the wider repertoire of antibodies against the S protein.
One of the key public health strategies in coronavirus 2019 disease (COVID-19) management is the early detection of infected individuals to limit the transmission. As a result, serological assays have been developed to complement PCR-based assays. Here, we report the development of a flow cytometry-based assay to detect antibodies against full-length SARS-CoV-2 Spike protein (S protein) in COVID-19 patients. The assay is time-efficient and sensitive, being able to capture the wider repertoire of antibodies against the S protein.
